New drug shows promise in shrinking breast cancer before surgery
NCT ID NCT04647487
First seen Nov 12, 2025 · Last updated Apr 29, 2026 · Updated 20 times
Summary
This study tested a new drug called LY3484356 in 87 postmenopausal women with early-stage (stage I-III) estrogen receptor-positive, HER2-negative breast cancer. The drug was given for a short time before surgery to see if it was safe and how it affected the cancer cells. The main goal was to measure changes in estrogen receptor levels and a cell growth marker called Ki-67 in tumor samples taken before and after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Barts Cancer Institute
London, London City, EC1A 7BE, United Kingdom
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Helios Kliniken Schwerin
Schwerin, Mecklenburg-Vorpommern, 19049, Germany
-
Hospital Clinic I Provincial
Barcelona, 08036, Spain
-
Hospital General Universitario Gregorio Marañon
Madrid, 28007, Spain
-
Hospital Madrid Norte Sanchinarro
Madrid, 28050, Spain
-
Hôpital René Huguenin
Saint-Cloud, Hauts-de-Seine, 92210, France
-
Institut Jules Bordet
Brussel - Capital, 1070, Belgium
-
Klinikum der Universitaet Muenchen
München, 80336, Germany
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Northwestern Memorial Hosptial
Chicago, Illinois, 60611, United States
-
Sarah Cannon Research Institute SCRI
Nashville, Tennessee, 37203, United States
-
The Royal Cornwall Hospital
Truro, Cornwall, TR1 3LJ, United Kingdom
-
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, 3000, Belgium
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
-
Universitätsklinikum Erlangen
Erlangen, Bavaria, 91054, Germany
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Winship Cancer Center Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.